Clinical reference

Presbyopia (age-related close-up vision loss)

Treatment options, dosing, cautions and Egyptian brands from the shipped Dawaa Reference card.

Evidence status

Checked against the sources named below

Sources5 sources

ICPC-3 (WONCA International Classification of Primary Care, 3rd edition) class FD69.03 - condition scope only, no dose · No dose - referral pathway, no medicine given in primary care · Presbyopia - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK560568/ · Presbyopia - disease-level clinical article (presbyopia-full.txt) · VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% US prescribing information, section 1 Indications and Usage, section 2 Dosage and Administration and section 5 Warnings and Precautions (DailyMed SetID 8d806897-8a2a-4518-8c68-0ec3b778de50)

Verified against3 documents

No dose - referral pathway, no medicine given in primary care
Presbyopia - disease-level clinical article (presbyopia-full.txt)
VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% US prescribing information, section 1 Indications and Usage, section 2 Dosage and Administration and section 5 Warnings and Precautions (DailyMed SetID 8d806897-8a2a-4518-8c68-0ec3b778de50)

Verified date2026-08

Presentation reference

Is it this?

Reference only, to read alongside your own examination.

Symptoms — what the patient reports (5)

Progressive trouble focusing on near objects, worse in dim light or during prolonged close work, is the hallmark complaint [inattention]
Eye strain, fatigue, headache, and holding reading material at arm's length are common accompanying complaints [fatigue · headache]
Distance vision is usually unaffected, particularly in people without any underlying refractive error
Complaints emerge earlier in people with heavy screen-time exposure because of latent accommodative dysfunction
Delayed refocusing between near and distance, squinting, drowsiness during close work, and needing bright light to read round out the picture [drowsiness]

Signs — what you find (3)

Near visual acuity declines while distance acuity stays normal or close to normal
The near point of accommodation moves beyond the patient's usual reading distance
A light aimed from the front of the patient's face creates a false pin-hole effect that widens apparent depth of focus, so it must shine from behind instead

Tests (6)

Jaeger or Rosenbaum near-vision cards at a fixed reading distance grade how severe the near-vision loss is
Accommodative amplitude is measured with the push-up test or minus-lens technique to confirm the diagnosis
Slit-lamp exam checks the anterior segment for dry eye, which can worsen near-vision complaints
Intraocular pressure measurement and a fundus exam are done to exclude glaucoma and macular degeneration in older patients
The prescribed power is the weakest plus lens needed for the patient to make out the bottom line of a near card held where they normally read
Cycloplegic refraction uncovers latent hyperopia in patients under 45 who have early presbyopia-like complaints

If not this — what else fits (8)

Accommodative insufficiency affects younger people and stems from a failing accommodative system rather than age-related lens change, and it can sometimes be reversed with vision therapy
Convergence insufficiency or excess should be excluded, especially with double vision or a frontal headache while reading
Latent hyperopia can cause near-task strain despite normal distance vision because of an unmasked hyperopic error demanding extra accommodative effort
An early nuclear sclerotic cataract can mimic presbyopia through a myopic shift, or apparent improved near vision known as second sight
Dry eye and digital eye strain from heavy screen use can blur near vision and cause discomfort resembling presbyopia
Neurologic disease such as progressive supranuclear palsy or a cranial nerve palsy can impair accommodation or convergence, mimicking near-vision loss
In macular disease, vision fails to improve with refractive correction, unlike presbyopia, and retinal OCT shows the abnormality
A posterior subcapsular cataract differs from presbyopia in that near vision worsens further in bright light

SourceStatPearls "Presbyopia" - disease-level clinical article

Presentation findings are traced to the source above.

Rx: Main treatment | Miotic drop that buys a few hours of near vision - an adjunct to reading glasses

MAIN TREATMENT

OPTICAL CORRECTION (RECOGNITION & REFERRAL)

1st line

Adult dose and duration

Normal age-related loss of near focusing power, affecting almost everyone from the mid-forties. The definitive management is OPTICAL and it is not a prescription: reading glasses, bifocals, or progressive addition lenses, or multifocal / monovision contact lenses. Correcting the optics is the article's main opening strategy, the more so early on, and the options it lists are bifocals, single-vision reading glasses, and progressive addition lenses. Refer for refraction; surgical options exist for those who want to be spectacle-free. - Refer

Paediatric dose

Adult-only condition - paediatric section not applicable

Dose source

No dose - referral pathway, no medicine given in primary care

Why

Cautions

Sudden vision change not explained by normal gradual presbyopia should be referred promptly.
The drug row below can be recognised but not dispensed in Egypt. The one licensed pharmacological option the article names is pilocarpine 1.25% eye drops (Vuity, FDA-approved 2021), and no product at that concentration is on the Egyptian register - what the register holds is pilocarpine at 1%, 2%, 3% and 4%, which are glaucoma strengths and a different medicine at the point of care. The article states no frequency for it either. What it says the drug does: the 1.25% ophthalmic solution, licensed by the FDA in 2021 under the name Vuity, has been shown to improve near vision by constricting the pupil and so deepening the focus. What it says about the limits: the effect is temporary, running 6 to 10 hours, and it can bring headache, brow discomfort and poorer night vision as the pupil narrows.
Warn about the adaptation period or the patient will abandon the glasses. On the article's account neither bifocals nor progressives are tolerated well at first: they can bring on nausea and dizziness, and because vision quality shifts at the junction between lenses, the patient may misjudge depth while walking. With continued wear the symptoms settle over 2 to 3 weeks. (Presbyopia - StatPearls - NCBI Bookshelf, NBK560568)

MIOTIC DROP THAT BUYS A FEW HOURS OF NEAR VISION - AN ADJUNCT TO READING GLASSES

PILOCARPINE

Miotic drop that buys a few hours of near vision - an adjunct to reading glasses

2nd line

Formeye

Adult dose and duration

One drop in each eye once daily, with an optional second drop the same day. US label verbatim: "The recommended dosage of VUITY is one drop in each eye once daily. A second dose (one additional drop in each eye) may be administered 3-6 hours after the first dose." Strength verbatim: "VUITY (pilocarpine hydrochloride ophthalmic solution) is a clear, colorless, sterile ophthalmic solution containing 1.25% (12.5 mg/mL) of pilocarpine hydrochloride." Spacing verbatim: "If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart." - Each dose lasts hours, so it is used on the days near vision is needed rather than taken as a standing treatment. The disease article puts the effect at 6 to 10 hours and calls it transient, and lists headache, brow discomfort and poorer night vision - the pupil being constricted - among the possible adverse effects.

Paediatric dose

Adult-only condition - paediatric section not applicable

Dose source

VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% US prescribing information, section 1 Indications and Usage, section 2 Dosage and Administration and section 5 Warnings and Precautions (DailyMed SetID 8d806897-8a2a-4518-8c68-0ec3b778de50)

Why

StatPearls names the drug, its strength and its brand: a 1.25% pilocarpine ophthalmic solution, FDA-approved in 2021 as Vuity, which narrows the pupil to sharpen close-up focus and so improves near vision. The US label's only licensed use is treating presbyopia in adults. The card carried spectacles and contact lenses alone, and those remain the mainstay - the article lists the drug as a pharmacological option alongside them, not in their place.

Cautions

RED FLAG - retinal detachment. US label verbatim: "Rare cases of retinal detachment and retinal tear have been reported with miotics, including VUITY. Individuals with pre-existing retinal disease are at increased risk. Therefore, examination of the retina is advised in all patients prior to the initiation of therapy. Patients should be advised to seek immediate medical care with sudden onset of flashing lights, floaters, or vision loss." Myopia and prior retinal disease are the patients to think about before writing it.
Night driving is the practical hazard. US label verbatim: "Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision)." and "Exercise caution in night driving and other hazardous activities in poor illumination." A constricted pupil in Cairo traffic after dark is a real cost.
Not while the eye is inflamed. US label verbatim: "VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and the lens."
Contact lenses come out first. US label verbatim: "Contact lens wearers should be advised to remove their lenses prior to the instillation of VUITY and to wait 10 minutes after dosing before reinserting their contact lenses."
The Egyptian pilocarpine eye drops are not this product. ISOPTO CARPINE and OCUCARPINE are 1% and 2% glaucoma drops; the presbyopia dose is a 1.25% solution studied and licensed for that use. A stronger glaucoma drop is a different medicine at a different concentration, and substituting it is not the regimen the label describes.

Egyptian brands

No Egyptian brand matched — prescribe by generic name.

Prices are indicative (dataset snapshot 2026-06); verify with the pharmacy.